Szyman Catherine M.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed Dec 17, 2021
- Accession no.
- 0001225208-21-015136
- Filed
- Dec 17, 2021
- Trade date
- Dec 17, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.21M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Szyman Catherine M.CIK 0001438538 | Officer (CVP, Critical Care) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2021 | Common Stock | MOption exerciseAcquired | +10,000 | $21.76 | +$217,600 | 37,414.52 | Direct | |
| Dec 17, 2021 | Common Stock | SSaleDisposed | −10,000 | $121.24 | −$1,212,400 | 27,414.52 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2021 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 93,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.